Oropouche virus (OROV) is responsible for outbreaks of Oropouche fever in parts of South America. We recently identified and isolated OROV from a febrile Ecuadorian patient, however, a previously published rRT-PCR assay did not detect OROV in the patient sample.
Introduction
Oropouche virus (OROV) is the causative agent of Oropouche fever, an arboviral illness that is usually self-limiting and mild but in rare cases infects the central nervous system and causes meningitis (1, 2) . The virus belongs to the genus Orthobunyavirus, family Peribunyaviridae, and has a negative-sense, single-stranded RNA genome composed of three segments. The small (S) segment (0.95 kb) encodes the nucleoprotein (N) and non-structural protein (NSs), the medium (M) segment (4.36 kb) encodes a polyprotein consisting of two glycoproteins (Gn, Gc) and one non-structural protein (NSm), whilst the large (L) segment (6.85 kb) encodes the RNA dependent RNA polymerase (RdRP) (3) .
OROV is one of the most clinically important orthobunyaviruses in the Americas, with over half a million cases and more than 30 major outbreaks reported since it was first isolated in Trinidad and Tobago in 1955 (4) . These figures are likely to be underestimates, caused in part by underreporting due to the similar clinical presentation of other arboviral diseases that co-circulate in the same areas, including dengue virus (DENV), chikungunya virus (CHIKV), Mayaro virus (MAYV), yellow fever virus (YFV) and Zika virus (ZIKV) (4, 5) . Cases of Oropouche fever have been reported in Brazil, Peru, Panama, and Trinidad and Tobago (5) . We recently isolated OROV for the first time from a patient in north-western Ecuador (6) , suggesting that OROV may be circulating undetected in this region. This led us to further investigate the presence of OROV in an additional 196 febrile patients from the same coastal area of Esmeraldas, Ecuador, sampled in 2016.
Reverse transcription polymerase chain reaction (RT-PCR) is typically used for the detection of viral RNA directly from clinical samples (7) (8) (9) (10) . The rate of detection of OROV RNA in patient plasma during the first five days of illness is reported as 93.3% using a onestep real-time RT-PCR (rRT-PCR) (7) . A disadvantage of RT-PCR is that a conserved target genome sequence is required, making it difficult to detect viral strains that are genetically divergent, reassortant, novel, or of an unexpected virus species. Metagenomic sequencing (untargeted sequencing of all genetic material in a sample) is an attractive alternative to conventional molecular detection methods as it does not require prior knowledge of pathogen genome sequences. For example, an established OROV rRT-PCR (7) was unable to detect OROV in the plasma of an Ecuadorian febrile patient who tested positive using metagenomic sequencing and virus isolation (6) . This highlights the potential for misdiagnosis when screening for pathogens that lack a large collection of reference sequences on which to base targeted amplification. Here we report (i) the development of a rRT-PCR with improved sensitivity, (ii) an algorithmically-designed (11) primer set for whole-genome amplification of OROV, and (iii) the prevalence of OROV in the 2016 Esmeraldas patient cohort.
Materials and methods

Patient samples
Plasma samples were obtained from patients at Delfina Torres de Concha Hospital, Esmeraldas province, Ecuador, in 2016 (n=196) and 2017 (n=62), along with metadata: patient age, sex, patient location, number of days of fever, and other clinical signs and symptoms. Use of these samples in this study was approved by the bioethics committee of Universidad San Francisco de Quito, Ecuador.
RNA extraction and PCR assays
Plasma samples were spiked with bacteriophage MS2 (1.45 x 10 5 pfu) as an internal control. RNA was extracted using the QIAamp Viral RNA mini kit (Qiagen) following manufacturer's instructions, substituting the addition of carrier RNA with the same volume of linear polyacrylamide (LPA). A negative extract control (molecular-grade water) was included in each batch of extractions. RNA was screened for DENV, CHIKV, ZIKV, YFV, MAYV, Plasmodium spp., Leptospira spp. and Rickettsia spp., using Public Health England in-house diagnostic PCR assays.
Metagenomic sequencing
DNAse treatment, cDNA preparation, random amplification by SISPA (Sequenceindependent Single Primer Amplification), and Illumina sequencing were performed as described previously (12) . Reads were trimmed to remove adaptors and low-quality bases using trimmomatic (0.3.0) (13) with default parameters, to achieve an average phred score of Q30 across the read. Samples with >0.02% reads assigned to a virus species by Centrifuge or an assembled scaffold larger than 1500 bp showing homology to a viral sequence using BLASTx were investigated for the presence of that specific virus. A positive virus detection was defined as >40% genome coverage (1x) generated when mapping to a reference genome.
Virus isolation
Vero cells, freely provided by the European Collection of Authenticated Cell Cultures (ECACC; catalogue number 84113001), were inoculated with patient plasma diluted 1:10 in Eagle's minimum essential medium (MEM) to a volume of 1 mL, incubated at 37°C with 5% CO2 for 96 hours. Cultures were sampled at 24-hour intervals, replication was determined using OROV rRT-PCR. Virus was harvested, filtered (0.2 μm pore, Sartorius) and stored at -80°C.
Primer alignment
Primer and probe sequences were aligned using the ClustalW algorithm in the MEGA7 software package to a set of OROV N gene coding sequences (Genbank), representing the geographic (Brazil, Panama, Peru and Trinidad and Tobago) and temporal diversity of OROV isolates from the 1950s to present day (Gutierrez et al., preprint link (bioRxiv) pending).
rRT-PCR limit of detection analysis
For OROV rRT-PCR assay optimisation (supplementary material), a range of primers were tested (supplementary material, table S1) using Invitrogen Superscript III Platinum One-step Quantitative RT-PCR kit (Invitrogen) in a standard 25 µL reaction, run on an ABI 7500 real-time PCR machine (Applied Biosystems). Optimal conditions were 18 µM of each primer, 12.5 µM probe and standard MgSO4 concentration. Cycling conditions: 50°C for 10 minutes, 95°C for 2 minutes, 45 cycles of 95°C for 10 seconds then 60°C for 40 seconds (with quantification analysis of fluorescence performed at the end of each 60°C step) and a final cooling step of 40°C for 30 seconds.
Absolute quantitation of RNA copy number was calculated from a standard curve of target sequence RNA, transcribed using the Megascript kit (Ambion). A 711 bp region of the S segment was amplified from cDNA of OROV/EC/Esmeraldas/087/2016, using primers incorporating a T7 promoter sequence (forward primer sequence GTC AGA GTT CAT TTT CAA CGA TGT ACC ACA ACG G, reverse primer sequence GAA ATT AAT ACG ACT CAC TAT AGG G CTC CAC TAT ATG TC). RNA was quantified using the Qubit RNA broad spectrum kit and purity confirmed using the RNA 6000 pico kit on a bioanalyzer (Agilent).
Multiplex tiling PCR primer design
The S, M and L segment sequences of OROV/EC/Esmeraldas/087/2016 were concatenated and inputted using default settings to the Primal Scheme (11) webtool (http://primal.zibraproject.org/), which implements an algorithm for designing multiplex PCR primers for virus lineages. The designed primer scheme was subsequently modified manually to account for segment ends, incorporating 5' and 3' end primers (see supplementary material for primer sequences).
RNA from patient sample D-057 and the cell-cultured prototype strain were amplified in two multiplex PCR reactions using the Ecuador OROV primers designed as described above. Primer pools were used at 100 μM. Products were visualised by gel electrophoresis and quantified using Qubit fluorometric quantitation. These were sequenced on a MinION (Oxford Nanopore, UK) and data processed as previously described (11) .
Results
Development of an OROV rRT-PCR
An existing S segment assay (7) failed to detect OROV RNA in an Ecuadorian clinical sample that tested positive by both metagenomic sequencing and virus isolation ( Figure 1 ) (6) . The reverse primer (OROV R) (7) had two mismatches to the novel OROV/EC/Esmeraldas/087/2016 sequence. We attempted to improve sensitivity by analysing primer and probe suitability. Two new reverse primers were designed; one with mismatches corrected (Ec R) and one at a new site (Ec2 R) (supplementary material, table S1), based on an alignment of all publicly available OROV S segment sequences. Testing was performed against both OROV/EC/Esmeraldas/087/2016 and the 1955 prototype Trinidad and Tobago isolate from a distinct lineage (Genbank KP026181.1). The original reverse primer showed reduced sensitivity for the Ecuadorian strain, compared with the prototype strain ( Figure 2 ). Primer Ec R showed improved sensitivity for the Ecuadorian strain, but reduced sensitivity for the prototype strain. Ec2 R improved sensitivity by three logs for the Ecuadorian strain and by one log for the prototype strain, compared with the original reverse primer. The final assay using Ec2 R underwent validation. The standard curve demonstrated a linear relationship between mean Cq value and log RNA copy number, the absolute limit of detection of the rRT-PCR assay was 10 copies of OROV RNA at a mean Cq value of 38.25 (95% CI 37.8 to 38.7) (supplementary material, figure S1). No crossreactivity was observed in exclusivity testing against 23 virus species (supplementary material, table S2) within the Alphavirus, Flavivirus, Phlebovirus, Orthobunyavirus, Nairovirus and Mammarenavirus genera. Primer and probe sequences were aligned with all publicly available OROV N gene sequences to identify mismatches that may reduce sensitivity for certain strains. Of the 149 sequences, 19 had mismatch(es) to the forward primer, 21 sequences showed a mismatch to the probe, and 26 had mismatch(es) to the original reverse primer OROV R, 6 of which were mismatches at two positions (supplementary material, table S3). In contrast, no sequence has more than one mismatch to the new reverse primer Ec2 R; however, the number of sequences with a single mismatch was higher (n=41). 
Pathogen identification in febrile patients using PCR
We initially used nine PCR assays to screen serum from Ecuadorian patients with undifferentiated febrile illness for pathogens previously reported from the country. Following our previous metagenomic sequencing based identification of OROV in one of these samples (6) , and improvement of the OROV rRT-PCR, we re-screened all patient samples for OROV 
Confirmation of OROV infection in PCR-positive patients, by virus isolation
OROV was successfully cultured in Vero cells from all five OROV positive patient plasma samples (virus was isolated from the initial patient D-087 as previously reported (6)).
Genome copy numbers for all samples increased by at least 5 logs to 1 x 10 12 
Development of an OROV multiplex tiling PCR primer scheme
Samples with lower levels of viral RNA often present problems in generating complete genome sequences using the metagenomic sequencing approach (Table 1, Figure   4 ). To address this problem, a set of targeted genome amplification primers was designed using the algorithmic method described by Quick et al. (11) . Using a cut-off of 20x read depth, >99% coverage of all three Ecuadorian OROV genome segments was obtained (average coverage of 7,075x , 9,894x and 7,381x for the S, M and L segments, respectively) directly from clinical sample D-057 ( Figure 5 ). For the prototype Trinidad and Tobago genome, 98% of the S segment (average coverage = 126,860x), 93% of the M segment (average coverage = 119x) and 92% of the L segment (average coverage = 189x) were obtained, despite its sequence divergence from the Ecuadorian strains. 
Discussion
Using metagenomic sequencing followed by screening using an optimised rRT-PCR, we have detected a cluster of six OROV cases from patients local to Esmeraldas, Ecuador, providing further evidence that OROV may be causing an unrecognised burden of human disease in previously unreported areas.
Some of these cases were not detected by the previously published assay due to a primer mismatch with the Ecuadorian genomes, which was identified in the metagenomic sequencing data. This discovery highlights the problems in developing amplification-based detection assays for pathogens with limited genomes, and the benefits offered by unbiased sequencing technologies. Although the cost associated with metagenomic sequencing may be prohibitive for frontline diagnosis in developing countries, it can be used in prospective screening studies to identify potential issues with rRT-PCR assays and allow for more alterations to increase inclusivity as reported here. We developed a new reverse primer for the previously-published assay that improves sensitivity for both the Ecuadorian strain (capable of detecting 10 copies of target RNA) and the genetically divergent prototype strain.
Other OROV strains were not available to validate against, however an alignment of all publicly available strains showed that the majority of sequences are homologous to the primer/probe sequences. The rRT-PCR amplifies a region in the S segment, the target sequence of which is shared by a number of reassortant orthobunyaviruses, including Iquitos virus, which is known to circulate in neighbouring Peru and can cause Oropouche fever (21) .
This modified assay also has the potential to detect reassortant orthobunyaviruses containing OROV S segment. An algorithmically-designed multiplex primer set was developed that can amplify the majority of the genome from both Ecuadorian and prototype strains and may be a useful tool for sequencing OROV genomes from clinical samples with low viral titres.
Virus identification in the Ecuadorian cohort was undertaken initially using PCR. In addition to OROV, screening identified the presence of ZIKV, DENV, CHIKV and Leptospira spp. nucleotide sequences. These pathogens are known to circulate in Ecuador It is well-documented that mutations occur during passaging in vitro (28) . Our study generated complete genome sequences from viruses that had undergone one passage in Vero cells. The single passage was necessary to amplify virus and generate complete genome sequences, however, passaging was limited to minimise the number of mutations between patient and cultured viral genomes. A number of positions in the OROV patient genomes
show a mixed population of variants, which progressed to a majority population in the cultured genome. Majority-majority changes were rare, and none of the SNPs observed between a patient and cultured genome were shared between strains. OROV infection should be considered when diagnosing Ecuadorian patients with febrile illness. We hope that the molecular tools developed in this study will be useful for laboratories performing viral diagnostics and surveillance in the Americas. Very little is known about the dynamics of OROV in Ecuador or endemicity in neighbouring regions; the detection of OROV in multiple febrile patients, described here, warrants further investigation into its prevalence, associated vectors, and transmission.
No cases of
